Seeking Alpha: Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis

The article covers Trium’s position as a significant shareholder in Acelyrin and its decision to vote against the proposed all-stock transaction at the company’s upcoming shareholder meeting.

Commenting on the proposal, Trium argued that the merger significantly undervalues Acelyrin relative to its cash position and does not adequately compensate shareholders for the risks associated with Alumis’ development pipeline. The article also highlights Trium’s view that current market conditions and the market’s assessment of Acelyrin’s lead asset do not justify pursuing the transaction at a discount to cash value.

Trium stated that it does not believe the proposed combination represents the most attractive outcome available to Acelyrin shareholders and intends to vote against the merger.

The full article covering Trium’s position on the proposed Acelyrin-Alumis merger can be accessed on the Seeking Alpha website here.